Immunomodulatory activities of AM3 appear to be related with its positive effects on chronic type B hepatitis (CABH).(II)

Elorza, Félix López; Vílchez, J. González; Jiménez, Norma Martínez; Sada, G; Herrerías, J. M.; Vg, Villarrubia

doi:10.1016/0168-8278(90)91676-n

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The activity of AM3 on liver enzymes has been also reported in patients with chronic active hepatitis B (27). ALT normalization was accompanied with HBe antigen and HBV-DNA clearances together with intriguing evolutive changes in peripheral blood mononuclear cells (28). Acute-phase reactants: Cancer patients frequently show alterations in inflammatory response manifested by decreases in IL-l production (29) and monocyte chemotaxis (4).…”

Section: Discussionmentioning

confidence: 99%

AM3, an Oral BRM: Protective Agent against Iatrogenic Bone‐Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy

Villarrubia¹,

Marquez²,

Cobo³

et al. 1992

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

In five clinical trials AM3, a polysaccharide/protein biological response modifier, was given (3 g/day; two capsules, tid) to 79 breast cancer patients undergoing adjuvant radio- and/or chemotherapies. When compared with 68 control patients, AM3 provoked significant decreases in the incidence of bone-marrow hypoplasia (20.5% versus 61.1%). This marrow effect was also manifested in peripheral blood by higher levels of white blood cells, mononuclear cells and platelets in the AM3 treated group. The incidence of thrombocytopenia in patients receiving combined radio-chemotherapy only was 70% compared with 6% observed in patients also receiving AM3 treatment. Besides these hematological effects, AM3 palliated subclinical hepatic toxicity due to combined radio-chemotherapy. Finally, studies on acute-phase reactants, such as C-reactive protein, IgA. and factors B, C'3, and C'5 of the complement system, suggest that a modulation of hepatic inflammatory responses by AM3 appears to be essential for clinical effects described.

show abstract

Section: Discussionmentioning

confidence: 99%